Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy by Patel, Jeetesh V et al.
© 2009 Patel et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2009:5 801–810
Vascular Health and Risk Management
801
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Omega-3 polyunsaturated fatty acids: a necessity 
for a comprehensive secondary prevention 
strategy
Jeetesh V Patel 
inessa Tracey 
elizabeth A Hughes 
Gregory YH Lip
Haemostasis, Thrombosis and 
Vascular Biology Unit, University 
of Birmingham Centre for 
Cardiovascular Sciences, City Hospital, 
Birmingham, england, UK
Correspondence:  Jeetesh Patel  
Haemostasis,   Thrombosis and Vascular 
Biology Unit, University Department 
of Medicine, City Hospital, Birmingham, 
england, UK 
Tel +44 0121 507 5080 
Fax +44 121 554 4083 
email jeetesh.patel@swbh.nhs.uk
Abstract: Long-chain omega-3 polyunsaturated fatty acid (PUFA) supplementation has 
been used for the secondary prevention of fatal and nonfatal myocardial infarction (MI). 
However, the benefit of this therapy is frequently confused with other established treatments 
in the therapeutic strategy among such patients. We review the data on omega-3 PUFA use in 
secondary care and consider indications for its use which include post-MI and raised triglycerides. 
We suggest that the available evidence supports the use of omega-3 supplementation as part of 
the comprehensive secondary care package for post-MI patients.
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Introduction
Long-chain omega-3 polyunsaturated fatty acids (PUFA) supplementation is used 
in the secondary prevention of fatal and nonfatal myocardial infarction (MI).1 
The therapeutic actions of omega-3 PUFA are largely characterized by their ability to 
lower serum triglycerides, but additional less explicit cardio-protection mechanisms 
including reduced platelet aggregation, antithrombotic and fibrinolytic activities, 
antiarrhythmic effects, reduced blood viscosity, and anti-inflammatory properties 
have all been suggested.2,3
Several issues hinder the use of this treatment as part of a comprehensive 
cardiovascular disease management package that already includes antiplatelet agents, 
angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, anticoagulants, and 
lipid-lowering drugs. Specifically, the ‘additional’ benefits and mode of action of 
omega-3 PUFA supplementation for post-MI patients are not clear to clinicians, the 
arrhythmic benefits are poorly understood, and the indications for triglyceride lowering 
are commonly confused with the indication for post-MI secondary prevention.
This review addresses these issues, providing an overview of efficacy data on 
omega-3 PUFA in post-MI survivors.
Benefits of omega-3 in patients post-MI
Cardiovascular disease is a major health care focus as it accounts for nearly one half 
of all deaths in the developed and developing world,4–7 low-density lipoprotein (LDL) 
cholesterol is one of the major modifiable risk factors for cardiovascular disease8,9 
and clinical trials using LDL cholesterol-lowering interventions have established 
its benefits following an ischemic event.10 However, even among patients at target 
levels of LDL and total cholesterol, cardiovascular events still occur,11–13 particularly Vascular Health and Risk Management 2009:5 802
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among those patients who have survived a heart attack.14 
Indeed, MI is often followed by an impairment of cardiac 
function which increases the risk of reinfarction and heart 
failure amongst patients with coronary artery disease (CAD). 
Paradoxically, levels of serum cholesterol are typically low 
in heart failure,15 and an inverse relationship exists between 
circulating concentrations and prognosis, particularly in 
advanced patients.16,17
The Diet And Reinfarction Trial (DART)
DART was the first randomized controlled trial of dietary fish 
intake in secondary cardiovascular prevention.18 It examined 
the effects of dietary changes related to increased fatty fish 
intake in 2033 men diagnosed with MI followed for 2 years. 
There was a reduction of 29% in 2-year all-cause mortality 
(P = 0.05) after MI among men that followed a high fish 
intake diet and 16% reduction in the risk of ischemic heart 
disease events. The benefit of the high fish intake group 
started to manifest early and persisted throughout study 
duration.
The GiSSi-Prevenzione trial
In the Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Infarto Miocardico Prevenzione (GISSI-Prevenzione) 
trial, in which omega-3 PUFAs were used, participants had 
a relative risk reduction of 15% in the composite primary 
end point (total mortality, nonfatal MI, stroke) despite a lack 
of change in cholesterol levels.1
This trial was the key clinical study investigating 
various aspects of omega-3 PUFA effects on post-MI 
patients (n = 11,324). Patients were randomized into 
4 groups that included an omega-3 PUFA capsule contain-
ing 84% eicosapentaenoic acid (EPA) and docosahexae-
noic acid (DHA) 1 g/day, vitamin E (alpha-tocopherol 
300 mg/day), a combination of omega-3 PUFA and 
vitamin E or no treatment. Male and female patients from 
across Italy with recent (3 months) MI were eligible 
and this included both ST segment elevation (STEMI) 
and non-ST segment elevation (NSTEMI) on electrocar-
diographic evidence. Age was not a restriction for entry 
into the trial and the mean age of the participants was 
59.4 years. Importantly, patients were asked to adhere to 
cardiovascular treatments such as aspirin, beta-blockers 
and ACE inhibitors and statin therapy (some 5% at the 
start of the trial and 45% after 42 months, as clinical trial 
evidence of efficacy of these drugs was emerging). Mean 
levels of total cholesterol among patients at baseline were 
6.67 mmol/L, HDL levels were 1.33 mmol/L, and serum 
triglycerides were 2.27 mmol/L. After 6 months, levels of 
HDL and total cholesterol were largely unchanged, while 
triglyceride levels were reduced by 3.4% in the omega-3 
therapy group (P = 0.001).
The outcomes from the study showed that compared to 
the control group (no treatment), the patients taking omega-3 
PUFA showed relative risk reductions of 20% for all deaths, 
30% for cardiovascular deaths, and 45% for sudden deaths. 
Thus, there was a benefit of omega-3 PUFA therapy, which 
was over and above other secondary prevention drugs (beta-
blockers, antiplatelet drugs, ACE inhibitors, statins), albeit in 
a patient group subscribing to a Mediterranean diet.
The GISSI-Prevenzione trial has also provided additional 
data from ancillary publications. For example, the time-
course of the benefit associated with CHD patients surviving 
MI in the GISSI-Prevenzione trial was assessed by study 
investigators.19 On statistical survival analysis, Kaplan-Meier 
curves at 3 months following treatment with omega-3 PUFA 
showed a significant reduction in total mortality (compared 
to the control group), and a significant reduction in sudden 
death at 4 months. For sudden death, GISSI-Prevenzione 
investigators have also reported that omega-3 PUFAs are 
efficacious in the prevention of sudden death within high-
risk groups such as those with systolic dysfunction.20 Further 
details on the heart failure data from GISSI-Prevenzione are 
provided later.
Japan ePA Lipid intervention Study (JeLiS)
JELIS was a randomized, open-label, blinded, endpoint trial 
of highly purified EPA with statin vs statin-alone therapy for 
prevention of major coronary events in hypercholesterolemic 
patients.21 A total of 18,645 Japanese patients were randomly 
assigned to receive 1800 mg of highly purified EPA in addi-
tion to statin therapy and followed up for 4.6 years. Out of 
these patients, 14,981 were subject to primary prevention 
and 3664 to secondary prevention.
The relative risk reduction of major coronary events in the 
EPA group was 19%, with a 24% reduction in the frequency 
in the unstable angina. The occurrence of coronary death and 
sudden cardiac death was not significantly reduced. However, 
the frequency of nonfatal coronary events (including nonfatal 
MI, unstable angina, angioplasty, stenting, or coronary artery 
bypass) was significantly lower in the EPA group compared 
to the controls. Of note, the study population was likely to 
have high levels of serum EPA because of the high fish 
consumption in the Japanese population. Both EPA with 
statin and statin-alone treatments lowered LDL cholesterol 
by the same amount of 25%. Hence, the increased reduction Vascular Health and Risk Management 2009:5 803
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of major coronary events was likely to be unrelated to the 
LDL cholesterol-lowering effect per se.
Other evidence post-Mi
Studer et al published a systematic review on 97 lipid-
lowering trials carried out between 1965 and 2003.22 This 
included a total of 137,140 individuals subjected to interven-
tion and 138,976 in the control group. The selection of the 
trials was oriented towards comparison of individual drugs 
to placebo or usual care. Based on pharmacological character-
istics, the trials were divided into statin, fibrate, resin, niacin, 
omega-3 PUFA, and dietary intervention groups.
The omega-3 PUFA group included 14 trials with 9 trials 
on secondary cardiovascular disease prevention. The average 
relative reduction in total cholesterol was highest in the statin 
group and lowest in the omega-3 PUFA group. The risk 
ratios for overall mortality were not correlated with reduc-
tions in cholesterol level. Risk rates for cardiac mortality 
showed a significant reduction in the statin and omega-3 
PUFA treatment groups, as did the group on resin treatment. 
Thus, omega-3 PUFAs reduced overall mortality and cardiac 
mortality in patients with CAD. The estimated number to 
treat for 1 year in this group was 140 patients for second-
ary prevention to prevent 1 death, whereas for the statin 
group, the number to treat was 248 patients for secondary 
prevention. In primary prevention (with a mortality rate of 
below 1% per year) the number to treat was 855 patients to 
prevent 1 death. Similar to JELIS, this review also concluded 
that the benefits of omega-3 PUFA were not related to reduc-
tion in the cholesterol level.
Heart failure
Heart failure is an increasing cause of cardiovascular morbid-
ity and mortality within the Western world.23,24 Given that it is 
associated with marked impairment of quality of life, frequent 
hospital admissions, and poor prognosis25,26 (recognized to be 
worse than some cancers), heart failure is an important public 
health concern.27 MI is often followed by left ventricular 
systolic dysfunction (LVSD), and an increased risk of heart 
failure, and mortality.28–30 The symptoms and prognosis of 
CAD patients with LVSD are significantly improved by 
various cardiovascular therapies such as beta-blockers, ACE 
inhibitors, and spironolactone,31 which can delay or even 
prevent the progression of heart failure.
In the GISSI-Prevenzione trial the presence of overt 
congestive heart failure was an exclusion critera for the 
study. One could argue that this exclusion renders the GISSI-
Prevenzione trial less representative of a post-MI population. 
Nonetheless, left ventricular systolic function was monitored 
by echocardiography on 9630 patients enrolled in the trial.32 
These patients were stratified into 4 ordinal groups of ven-
tricular systolic function (ejection fraction 50%, 46% to 
50%, 45% to 41%, 40%). Omega-3 PUFA therapy across 
the groups reduced the total mortality within patients by 
24% (P = 0.02) in those with LVSD and nonsignificantly by 
19% in those without LVSD. Of note, patients with LVSD 
(ejection fraction 40%) had a 4-fold greater benefit from 
omega-3 PUFA treatment in the reduction of sudden death 
compared to those with normal systolic function (ejection 
fraction 50%). These benefits of omega-3 PUFA were 
independent of treatment with beta-blockers and ACE 
inhibitors.
This analysis of results from the GISSI-Prevenzione 
trial relating to LVSD were explorative and hypothesis-
generating, and this formed the basis for a large clinical 
trial to specifically test the effects of omega-3 PUFA in 
the setting of heart failure – the GISSI-HF trial.33 The aim 
of this randomized, double-blind, placebo-controlled trial 
was to determine whether omega-3 PUFA would improve 
mortality and morbidity among patients with chronic 
heart failure (New York Heart Association class II–IV, of 
any cause and with any level of left ventricular systolic 
function). In total, 3494 were randomly assigned to omega-3 
PUFA (1 g daily) and 3481 to placebo for a median time of 
3.9 years where primary endpoints were time to death and 
time to death or admission to hospital for cardiovascular 
reasons. Compared to the placebo arm, the omega-3 PUFA 
group resulted in a 1.8% absolute reduction in all-cause 
mortality and 2.3% reduction in mortality or admission 
for cardiovascular reasons. This small, albeit significant, 
benefit from omega-3 PUFA (1 g/day) was not seen in the 
other arm of the GISSI-HF Trial, in which statin therapy 
did not reach the same clinical outcomes.34 These results 
consolidated the indication for omega-3 PUFA therapy in 
post-MI patients.
Antiarrhythmic and antithrombotic 
effects of omega-3 PUFAs
Arrhythmias are common complications and account for a 
large proportion of death post-MI. Results from the GISSI-
Prevenzione trial show a significant reduction in sudden 
cardiac death of 45% over 3.5 years of follow-up.1 The 
reduction in risk of sudden cardiac death was reported to 
increase in significance with the duration of trial, becom-
ing highly statistically significant by the end of study. 
The benefits were particularly attributed to the reduction Vascular Health and Risk Management 2009:5 804
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of lethal arrhythmias, rather than cholesterol-lowering or 
anticoagulant effects per se.1
The mechanism of action of omega-3 PUFA is multifac-
eted. Low heart rate variability is associated with increased 
morbidity and mortality in post-MI patients.35–37 Indeed, 
Christensen et al reported an increase in heart rate vari-
ability with use of omega-3 PUFAs.38,39 However, Hamaad 
et al reported no changes in indices of heart rate variability 
(HRV) in patients post-MI after 3 months treatment of 
omega-3 PUFAs with the dose used in the GISSI-Prevenzione 
study.40 Direct correlations between the level of omega-3 
PUFA in cell membranes and HRV indices have also been 
reported.41 Observations in vitro and in vivo imply that the 
antiarrythmogenic effect is related to the modulation of the 
Na+ and Ca2+ currents in the myocyte sarcolema, electrical 
stabilization of cardiomyocytes, enhanced myocardial effi-
ciency, and increased resistance to reperfusion arrhythmias.42 
Infusion of an emulsion of omega-3 PUFAs on an exercising 
dog model with surgically produced MI prevented ischemia-
induced sudden cardiac death by preventing ventricular 
fibrillation.43
Recent studies suggest that omega-3 PUFAs have a 
protective effect against fatal ventricular arrythmias, par-
ticularly in post-MI patients,1 and atrial fibrillation (AF).44 
AF is the most common complication after coronary artery 
bypass surgery (CABG).45 Calo et al conducted the first 
trial investigating the efficacy of perioperative treatment 
with n-3 PUFAs in preventing AF in patients undergoing 
CABG. The results of this open-label randomized con-
trolled study show not only a significant reduction in the 
incidence of postoperative AF events but also a reduction 
in the hospital stay.46 There was a relative risk reduction 
of 54.4% and an absolute risk reduction of 18.1%, the 
effect being similar to that of the beta-blockers sotalol and 
amiodarone currently used for this purpose, and having a 
further benefit of being well tolerated and safe to use in 
the majority of patients.
There is evidence among patients with implantable 
cardioverter defibrillators that suggest that omega-3 PUFAs 
do not reduce the risk of ventricular tachycardia/ventricular 
fibrillation and may actually be pro-arrhythmic.47 These 
studies include patients with ventricular arrythmias without 
the ischemic background or recent MI, and hence different 
mechanisms of arrhythmia development.47 However, a recent 
study in patients with idiopathic dilated cardiomyopathy by 
Nodari et al found a beneficial effect in parameters related to 
arrhythmic risk independent from the anti-schemic effects, 
although again this was a small study.48 The trials published 
to date in nonischemic arrhythmia patients have either been 
inconclusive49 or underpowered.47,48,50
It is possible that omega-3 PUFAs can have antiarrhyth-
mogenic or proarrhythmogenic effects depending on the 
origins of arrhythmias, and this question remains open for 
larger randomized controlled trials. In a study comparing the 
effects of different types of dietary fish consumption, baked 
and broiled fish intake (tuna) was associated with lower risk 
of incident AF, a situation which was reversed among people 
eating fried fish or fish sandwiches. However, this observed 
relationship may be related to other environmental factors 
associated with both fish intake and risk of AF.51
Sudden cardiac death events are not related only to the 
arrhythmogenic effects, and in many instances have a throm-
botic basis. Some studies attribute the anti-inflammatory 
effect of the omega-3 PUFAs to the suppression of pro-
inflammatory cytokines, such as interleukin 6, interleukin 
1β and tumor necrosis factor α production.52,53 In addition, 
a reduction of platelet count and augmentation of fibrinolytic 
activity has been reported, and would be expected to reduce 
the potential for thrombus formation. Conversely, other 
studies have not found significant changes in prothrombosis 
markers with omega-3 PUFAs.54,55
Overall, there is no strong indication for the antithrom-
botic hypothesis of omega-3 PUFAs, and we have to conclude 
that on current evidence the major effect may perhaps be 
antiarrhythmic rather than antithrombotic.
Direct effects of omega-3 PUFAs 
on the heart
Despite clinical trial evidence of efficacy for post-MI and 
heart failure patients, it remains unclear as to whether 
omega-3 PUFAs have a direct effect on the heart. Little is 
known about the influence of omega-3 PUFA supplements 
on energy homeostasis in post-MI patients, where the 
competitive balance between glucose and nonesterified fatty 
acids (NEFA) may have a crucial impact on the vitality of 
the myocardium following ischemic damage.56
Metabolic disturbances following Mi
Physiologically, for the myocardium to contract, the heart 
must successfully transform chemical energy into mechanical 
energy. Cytosolic mitochondrial oxidative phosphorylation 
of ADP to ATP is employed by the heart to fulfil this task, 
for which it requires oxygenated blood and a fuel source. The 
fuel requirements (determined by body size and composition, 
age, and gender) are met by glucose (4 kcal/g) or NEFA 
(9 kcal/g). The preferred fuels for myocardial oxidative Vascular Health and Risk Management 2009:5 805
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metabolism are glucose (3:1) in the fed state, NEFA during 
fasting, and NEFA and lactate during exercise.56 Energy is 
derived from accessible stores of glycogen (for glucose) and 
triglyceride (for NEFA).
Acute myocardial ischemia generates a chain of com-
pensatory metabolic reactions that are directed to preserve 
cardiac function in an environment of decreasing myocardial 
oxygen supply. Decreasing mitochondrial respiratory chain 
ATP production in the cardiac muscle is then met by an 
increase in glycolysis. Under oxygen-limiting conditions, 
glycolytic activity results in the formation of lactate and 
only a small fraction of the energy normally released from 
glucose aerobically is generated. Further electron transport 
activity associated with anaerobic glycolytic activity results 
in proton production (which would normally act as substrate 
for energy and water synthesis in the presence of oxygen). 
Excessive lactate and proton production promotes acidosis 
and damage (either direct action or through free radical 
formation) to the myocardium that further decrease cardiac 
efficiency at a crucial stage.57,58
Omega-3 PUFAs and fatty acid oxidation 
in the ischemic myocardium
NEFA concentrations are raised and sustained throughout the 
process of severe ischemia and MI.59 Indeed, large infarcts 
have been associated with high plasma concentrations of fatty 
acids.10 Acute stress and pain at the time of MI is associated 
with an increase in circulating catecholamines, promoting the 
hydrolysis of NEFA from adipose stores.60 Effectively, high 
concentrations of circulating NEFA and low levels of insulin 
during (and after) the ischemic period ensure that metabolism 
within the myocardium is preferentially directed towards the 
oxidation of NEFA instead of glucose. Of note, the highly 
reduced structures of NEFA create an oxygen demand that 
is much higher than that required for the complete oxidation 
of glucose. Anaerobic metabolism of NEFA also results in 
the formation of glycolytic metabolites that are manifest as 
excessive lactate, proton production, free radical formation, 
and intracellular acidosis. In addition, acyl CoA and acylcar-
nitine, products of fatty acid catabolism, are associated with 
cardiac membrane damage, enzyme loss, Ca2+ overload, and 
arrhythmias (see Figure 1).
In a pilot randomized study we investigated the effects of 
omega-3 PUFAs in addition to usual care on levels of insulin, 
NEFA, triglycerides, glucose and other indices of markers 
of energy homeostasis.61 Short-term therapy with Omacor® 
(Solvay Healthcare, UK) (Figure 2) did not significantly change 
circulating concentrations of metabolically active hormones, 
lipids or glycemic control. However, such therapy was 
associated with raised insulin levels compared to usual care.
Myocardium 
Acute stress and
pain  
Catecholamine
release  
Plasma NEFA
increase  
Plasma glucose
decrease  
Anaerobic
glycolysis
Tissue damage
through free
radical formation,
phospholipids and
lysophospholipids     
Membrane damage 
Enzyme loss,
proton overload
and arrhythmias   
Figure 1 effects of glucose and fatty acids on myocardial ischemia and arrhythmias.
Abbreviation: NeFA, nonesterified fatty acids.Vascular Health and Risk Management 2009:5 806
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There is also growing interest on the action of insulin 
on the myocardium to promote the extraction of glucose 
in the ischemic myocardium, kerbing the competitive 
edge of NEFA as a fuel source in this setting.62 Indeed, the 
antiarrhythmia action of omega-3 PUFAs could relate to an 
hyperinsulinemic effect among patients with MI. Perhaps 
omega-3 PUFAs could reduce the adverse effects of fatty 
acid toxicity on the myocardium (fatty acid phospholipid, 
lysophospholipid, and free radical formation). In support 
of such a theory, dietary intervention with omega-3 PUFAs 
has improved insulin sensitivity in overweight and obese 
European adults.63 Despite a major influence on metabo-
lism, omega-3 PUFA supplements have little effect on 
glycemic control, at least among hypertriglyceridemic 
patients.64,65
Serum triglycerides as a risk factor 
in patients post-MI
Raised triglycerides are an independent risk factor for 
CAD66 and there is also evidence that raised triglyc-
erides promote a synergistic risk through lipoproteins 
transporting triglycerides.67 In the Copenhagen Male Study, 
for example, which was an 8-year follow-up of 2906 men 
free of CAD, an increasing trend (P  0.001) between 
triglyceride concentration and CAD events was shown to be 
independent of other risk factors including HDL cholesterol 
concentrations.68 Other data from the Atherosclerosis Risk in 
Communities Study (ARIC), which was a 10-year follow-up 
of 12,339 middle-aged North American subjects, showed 
that triglycerides were an independent risk factor in women, 
when associated with CAD events.69 In the Physician’ Health 
Study, a prospective study of 14,916 adult men, nonfasting 
triglyceride levels were a strong and independent predictor 
of future risk of MI, particularly in the presence of elevated 
total cholesterol.70 One meta-analysis of 17 population-based 
studies estimated that elevated triglycerides were associ-
ated with a 30% increase in cardiovascular disease in men 
and a 75% increase in women.71 Despite ongoing debate as 
to whether triglyceride concentrations should be measured in 
a fasted state,72 these data essentially establish triglycerides 
as a risk factor for primary prevention of CAD.
In the four secondary-prevention trials of triglyceride 
lowering using fibrate drugs, a significant decrease in CAD 
events occurred in only one of these trials.73–76 Hence the 
efficacy of omega-3 PUFA for all-cause mortality may not 
necessarily involve triglyceride lowering per se. Nonetheless, 
hypertriglyceridemia is often the most common hyperlipid-
emia found in MI survivors.77
O
O
O
O
The structural formula of EPA ethyl ester is:  
The empirical formula of EPA ethyl ester is C22H34O2, and the molecular weight of
EPA ethyl ester is 330.51.  
The structural formula of DHA ethyl ester is: 
The empirical formula of DHA ethyl ester is C24H36O2, and the molecular weight of
DHA ethyl ester is 356.55.  
Figure 2 Omacor is a highly purified omega-3 fatty acid formulation containing 900 mg of the ethyl esters of omega-3 fatty acids in each 1 g capsule (a combination of ethyl 
esters of eicosapentaenoic acid [ePA – approximately 465 mg] and docosahexaenoic acid [DHA – approximately 375 mg]).Vascular Health and Risk Management 2009:5 807
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Pathophysiological considerations
Triglyceride deposits within adipose tissue are the major 
store of energy in the body. Triglycerides accumulate by the 
esterification of NEFA with glycerol-3-phosphate (G3P).78 
Hormone-sensitive-lipase (HSL) hydrolyzes adipocyte 
triglyceride to release NEFA into the circulation for uptake 
by skeletal muscle and liver during fasting.79 HSL is an 
intracellular enzyme under the control of both insulin and 
catecholamine release.80 NEFA levels at fasting are usually 
around 0.4 to 1.0 mmol/L.
During starvation, associated hormones stimulate 
hydrolysis, NEFA levels rise to 1.5 to 2.0 mmol/L after 
2 to 5 days of fasting.78 Triglycerides are transported in 
the blood upon lipoproteins – those made in the intestine 
called chylomicrons, and smaller triglyceride-rich 
lipoproteins made in hepatocytes called very low-density 
lipoprotein (VLDL). The role of chylomicrons and VLDL 
is thought to relate to a fuel (triglyceride) delivery system. 
On metabolism, these particles release free fatty acids 
and glycerol from triglycerides, and these generate a 
source of cholesterol. As triglycerides are hydrolyzed, 
VLDL is converted to intermediate-density lipoprotein 
(IDL) and then to remnant particles, known as LDL.77 
Triglyceride levels are nonparametrically distributed within 
populations and the upper limit of normal is considered 
to be 2.3 mmol/L77 although other studies suggest that 
triglyceride levels above 1.7 mmol/L are an indication of 
increased cardiovascular risk.81
Cardiovascular risk from raised 
triglycerides
The mechanism by which triglycerides promote atherogenicity 
may be difficult to separate from its synergistic effects on 
a host of lipid and lipoprotein variables, as well as other 
cardiovascular risk factors. For example, raised triglycerides 
are frequently manifest as part of a cluster of cardiovascu-
lar co-morbidities such as obesity, hypertension, insulin 
resistance, high blood pressure, and abnormal glucose and 
lipid metabolism.82–86 Moreover, the cardiovascular risk from 
raised serum cholesterol87 or low HDL cholesterol88 is much 
greater when triglycerides are raised.
The preponderance of LDL particles that are small and 
dense is another interrelated feature of the abnormal lipid 
distribution amongt individuals with raised triglycerides, 
providing an adverse consequence for cardiovascular 
risk.89,90 Patients with hypertriglyceridemia are also 
more likely to have a increased thrombotic risk91,92 and 
platelet activation.93 However, treatment with omega-3 
PUFA in combination with statin therapy can reverse 
these effects.94
Lowering triglycides using omega-3 
PUFAs in secondary care
The quantity of omega-3 PUFAs used in studies such as 
GISSI-Prevenzione trial was sufficient to significantly 
lower serum triglycerides. Also, Durrington et al investi-
gated the benefits of omega-3 PUFAs in doses that lower 
serum triglycerides in CAD patients with persisting 
hypertriglyceridemia (2.3 mmol/L) despite statin treat-
ment.95 Patients were randomized to receive Omacor 2 g 
twice daily or corn oil in identical capsules, as placebo, for 
24 weeks in a double-blind trial, after which both groups 
were invited to receive Omacor for a further 24 weeks. 
In patients receiving Omacor, there was a significant and 
sustained reduction of triglycerides (20% to 30%), with 
no adverse effects on HDL cholesterol, hematological and 
biochemical safety tests, or glycemic control. Interestingly, 
in another study of stable CAD patients (on statin therapy) 
with raised triglycerides, a reduction of approximately 
20% was demonstrated with just DHA 1 g daily. However, 
it is unclear whether a preparation of ‘pure’ DHA has the 
same efficacy for incident CAD events as ‘mixtures’ such 
as Omacor.96 While both EPA and DHA have triglyceride-
lowering effects, their impact on fatty acids metabolism 
differs.97
Conclusion
Given the public health focus on the epidemic of cardiovas-
cular disease, which accounts for nearly one half of all deaths 
in the developed and developing world,98 there is certainly 
scope for the inclusion of omega-3 PUFA therapy as part 
of a comprehensive cardiovascular disease management 
package. The evidence provided in this review underlines 
the efficacy of this treatment alongside antiplatelet agents, 
ACE inhibitors, beta-blockers, anticoagulants, and statins. 
Importantly, the additional benefits of omega-3 PUFA over 
these other treatments does not include the lowering of total 
or LDL cholesterol in post-MI patients. There is no evidence 
on whether concentrated preparations of omega-3 PUFA such 
as Omacor are interchangeable with individual preparations 
of DHA or EPA. The utility of omega-3 PUFAs in this patient 
group is possibly derived through its arrhythmic benefits and 
triglyceride lowering.
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